Advertisement
Canada markets close in 1 hour 34 minutes
  • S&P/TSX

    22,183.77
    -106.85 (-0.48%)
     
  • S&P 500

    5,184.80
    -2.90 (-0.06%)
     
  • DOW

    39,014.36
    +130.10 (+0.33%)
     
  • CAD/USD

    0.7283
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    79.03
    +0.65 (+0.83%)
     
  • Bitcoin CAD

    86,115.95
    -646.45 (-0.75%)
     
  • CMC Crypto 200

    1,328.84
    +34.17 (+2.64%)
     
  • GOLD FUTURES

    2,320.90
    -3.30 (-0.14%)
     
  • RUSSELL 2000

    2,050.64
    -14.01 (-0.68%)
     
  • 10-Yr Bond

    4.4900
    +0.0270 (+0.60%)
     
  • NASDAQ

    16,295.72
    -36.84 (-0.23%)
     
  • VOLATILITY

    13.10
    -0.13 (-0.98%)
     
  • FTSE

    8,354.05
    +40.38 (+0.49%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • CAD/EUR

    0.6776
    +0.0005 (+0.07%)
     

Introducing Endo International (NASDAQ:ENDP), The Stock That Tanked 91%

Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held Endo International plc (NASDAQ:ENDP) for half a decade as the share price tanked 91%. The falls have accelerated recently, with the share price down 37% in the last three months. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

View our latest analysis for Endo International

ADVERTISEMENT

Because Endo International is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Over five years, Endo International grew its revenue at 5.7% per year. That's not a very high growth rate considering it doesn't make profits. Nonetheless, it's fair to say the rapidly declining share price (down 38%, compound, over five years) suggests the market is very disappointed with this level of growth. We'd be pretty cautious about this one, although the sell-off may be too severe. We'd recommend focussing any further research on the likelihood of profitability in the foreseeable future, given the muted revenue growth.

Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGS:ENDP Income Statement, May 16th 2019
NasdaqGS:ENDP Income Statement, May 16th 2019

Endo International is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

We're pleased to report that Endo International shareholders have received a total shareholder return of 6.8% over one year. That certainly beats the loss of about 38% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

But note: Endo International may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.